KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor-Reference-Cited by-同舟云学术

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor

Published:2021-10 Issue:5 Volume:6 Page:100279
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Serna-Blasco R.,Sánchez-Herrero E.,Sanz-Moreno S.,Rodriguez-Festa A.,García-Veros E.,Casarrubios M.,Sierra-Rodero B.,Laza-Briviesca R.,Cruz-Bermúdez A.,Mielgo-Rubio X.,Sánchez-Hernández A.,Uribelarrea E.A.,Calvo V.,Romero A.^ORCID,Provencio M.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Therapeutic strategies to target RAS-mutant cancers;Ryan;Nat Rev Clin Oncol,2018

2. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient;Santos;Science,1984

3. Targeting KRAS-mutant non-small-cell lung cancer: one mutation at a time, with a focus on KRAS G12C mutations;Burns;J Clin Oncol,2020

4. KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC);Chen;Thorac Cancer,2020

5. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial;Jänne;J Am Med Assoc,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer;JCO Precision Oncology;2024-08

2. Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathway;Frontiers in Pharmacology;2022-10-28

3. Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation;Cancers;2022-09-13

4. Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors—Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?;Cancers;2022-07-07

5. Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner;Cancers;2022-03-23